Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption | Zendy

Wang Chang-yi | Zendy; Wing-Wai Wong | Zendy; HungChin Tsai | Zendy; YenHsu Chen | Zendy; Be-Sheng Kuo | Zendy; Shugene Lynn | Zendy; Jana Blažková | Zendy; Katherine E. Clarridge | Zendy; Hsiao-Wen Su | Zendy; Chia-Ying Lin | Zendy; Fan-Chen Tseng | Zendy; Annie Lai | Zendy; Fu-Hung Yang | Zendy; Chen-Han Lin | Zendy; William W. Tseng | Zendy; Hsiao-Yi Lin | Zendy; Connie L. Finstad | Zendy; Flossie WongStaal | Zendy; Carl V. Hanson | Zendy; TaeWook Chun | Zendy; MeiJune Liao | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption

Author(s) -

Wang Chang-yi,

Wing-Wai Wong,

HungChin Tsai,

YenHsu Chen,

Be-Sheng Kuo,

Shugene Lynn,

Jana Blažková,

Katherine E. Clarridge,

Hsiao-Wen Su,

Chia-Ying Lin,

Fan-Chen Tseng,

Annie Lai,

Fu-Hung Yang,

Chen-Han Lin,

William W. Tseng,

Hsiao-Yi Lin,

Connie L. Finstad,

Flossie WongStaal,

Carl V. Hanson,

TaeWook Chun,

MeiJune Liao

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1802264

Subject(s) - antibody , virology , human immunodeficiency virus (hiv) , virus , neutralizing antibody , medicine , antiretroviral therapy , immunology , viral load

Administration of a single broadly neutralizing human immunodeficiency virus (HIV)-specific antibody to HIV-infected persons leads to the development of antibody-resistant virus in the absence of antiretroviral therapy (ART). It is possible that monotherapy with UB-421, an antibody that blocks the virus-binding site on human CD4+ T cells, could induce sustained virologic suppression without induction of resistance in HIV-infected persons after analytic treatment interruption.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research